Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicySFHP Experimental Services Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentSan Francisco Health PlanPolicy CO-59

    Experimental or Investigational Services

    Customize your policy alerts

    Sign up for sanfranciscohealthplan Policy CO-59 alerts

    Get alerted when Policy CO-59 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs evaluation, prior authorization, coverage, denial, and appeal processes for experimental or investigational medical services, including drugs, devices, procedures, supplies, durable medical equipment, and related services.

    Policy Summary
    PayerSan Francisco Health Plan
    PolicyExperimental or Investigational Services
    Policy CodePolicy CO-59
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionRoute requests that may be experimental or investigational to an SFHP Medical Director for determination.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6Criteria for an investigational service exception
    10Requirements for Medicare IDE study coverage
    5 daysNotice of external review eligibility
    7 daysExpedited review target
    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Supporting published studies when applicable

    Experimental and Investigational Service Coverage

    General Investigational Service Coverage Exception

    SFHP may cover an investigational service when ALL of the following criteria are clearly documented in the member's medical records:

    ALL of the following

    • Conventional therapy will not adequately treat the intended patient's condition.
    • Conventional therapy will not prevent progressive disability or premature death.
    • The provider of the proposed service has a record of safety and success with it equivalent or superior to that of other providers of the investigational service.
    • The investigational service is the lowest-cost item or service that meets the patient's medical needs and is less costly than all conventional alternatives.
    • The service is not being performed as part of a research study protocol.
    • There is a reasonable expectation that the investigational service will significantly prolong the intended patient's life or maintain or restore a range of physical and social function suited to activities of daily living.

    Care Plus Medicare IDE Study Coverage

    Medicare allows payment of the routine cost of care for Medicare beneficiaries in certain categories of Investigational Device Exemption (IDE) studies. Category A and Category B IDE studies require prior authorization and are covered when ALL of the following requirements are met:

    ALL of the following

    • The principal purpose of the study is to test whether the device improves health outcomes of appropriately selected patients.
    • The rationale for the study is well supported by available scientific and medical information, or the study is intended to clarify or establish the health outcomes of interventions already in common clinical use.
    • The study results are not anticipated to unjustifiably duplicate existing knowledge.
    • The study design is methodologically appropriate, and the anticipated number of enrolled subjects is adequate to confidently answer the research question or questions being asked in the study.

    External Independent Review Eligibility

    A member is eligible for SFHP's external, independent review process for an experimental or investigational therapy only when ALL of the following criteria are met:

    ALL of the following

    • The member has a life-threatening or seriously debilitating condition.
    • The member's physician certifies that the member has a life-threatening or seriously debilitating condition for which standard therapies have not been effective in improving the member's condition, standard therapies would not be medically appropriate for the member, or there is no more beneficial standard therapy covered by SFHP than the therapy proposed.
    • ONE of the following

      • The member's physician, who is contracted with SFHP, has recommended a service, procedure, medical supply, durable medical equipment, or other therapy that the physician certifies in writing is likely to be more beneficial to the member than any available standard therapies.

    Terminal Illness Conference Appeal

    A member with a terminal illness may request a conference appeal after SFHP denies an experimental or investigational service when ALL of the following conference criteria are met:

    ALL of the following

    • SFHP's representative at the conference is an SFHP Medical Director serving as the staff member with authority to determine the resolution of the appeal.
    • The member and the member's representative may attend the conference telephonically or in person.
    • The member is given the opportunity to attend the conference within 30 calendar days of the denied authorization.
    • If the member's treating physician determines, after consultation with SFHP's Medical Director and based on standard medical practice, that the effectiveness of the proposed treatment would be materially reduced if it is not provided at the earliest possible date, the conference is held within five business days.

    SFHP does not cover investigational or experimental services. This exclusion does not apply to services related to qualifying clinical trials for the prevention, detection, or treatment of cancer or other life-threatening diseases or conditions outlined in CO-47: Clinical Trials.

    SFHP may cover investigational services under 22 CCR section 51303(h) when all applicable documentation and clinical criteria are met, as described above.

    This policy pertains to the Clinical Operations Department's process for evaluating medical services as investigational or experimental in nature. Refer to Pharm-02: Pharmacy Prior Authorization for the Pharmacy Department's evaluation of pharmaceuticals.

    Investigational or experimental services do not meet the criteria for medically necessary services because they are not standard medical practice.

    Services are investigational or experimental if any of the following apply: the requested service does not have unrestricted FDA market approval or final approval from another governmental regulatory body for treatment of a specified condition; there is insufficient or inconclusive medical and scientific evidence to evaluate the therapeutic value of the service; peer-reviewed medical literature provides inconclusive evidence that the service, procedure, medical supply, or durable medical equipment beneficially affects health outcomes; the service, procedure, medical supply, or durable medical equipment is not as beneficial as an established alternative; or there is insufficient information or inconclusive scientific evidence that, when used in a non-investigational setting, the service beneficially affects health outcomes or is as beneficial as an established alternative.

    Adequate evidence is defined as at least two documents of medical and scientific evidence indicating that the proposed treatment is likely to benefit the member. Interim approval granted as a step in the regulatory process does not substitute for final or unrestricted market approval.

    Authorization, Documentation, and Denial Requirements

    Prior Authorization

    Prior Authorization Required for IDE Studies

    Category A and Category B Medicare Investigational Device Exemption (IDE) studies in Care Plus require prior authorization before routine costs of care may be covered.

    • Coverage applies only when all applicable IDE study requirements are satisfied.
    Note

    Route Potentially Investigational Requests

    Utilization Management Outpatient evaluates requests that may be experimental or investigational. If an Outpatient Nurse identifies a request as potentially experimental or investigational, document the determination in the applicable JIVA authorization assessment and route it to an SFHP Medical Director; the Medical Director may consult MRIoA.

    Prior Authorization

    Policy Background

    SFHP characterizes experimental or investigational services as those that are not established standard medical practice or for which evidence of safety, therapeutic value, or beneficial health outcomes remains insufficient. Classification may apply when a service lacks unrestricted FDA or other governmental final market approval, when peer-reviewed evidence does not demonstrate beneficial outcomes, when an established alternative is more beneficial, or when evidence is insufficient to show benefit outside an investigational setting. Limited exceptions may be available when conventional treatment is inadequate or inappropriate and the policy’s coverage requirements are documented.

    Definitions and Evidence Standards

    Experimental/Investigational Therapy
    ScopeAny treatment, device, or procedure not currently approved as an accepted standard of practice.
    EvaluationSubject to rigorous ethical and scientific investigative methods.
    SettingEvaluated in a controlled setting.
    Experimental Services
    Services includedDrugs, equipment, procedures, or services in a testing phase.
    Testing stageLaboratory and/or animal studies are underway.
    Human testing
    Policy Summary
    PayerSan Francisco Health Plan
    PolicyExperimental or Investigational Services
    Policy CodePolicy CO-59
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionRoute requests that may be experimental or investigational to an SFHP Medical Director for determination.
    SourceLink
    On This Page
    Experimental and Investigational Service CoverageAuthorization, Documentation, and Denial RequirementsPolicy BackgroundDefinitions and Evidence Standards
    The study is sponsored by an organization or individual capable of successfully completing the study.
  1. The study complies with all applicable Federal regulations concerning the protection of human subjects found in Title 21 of the Code of Federal Regulations (CFR), Parts 50, 56, and 812, and Title 45, CFR, Part 46.
  2. Where appropriate, the study is not designed exclusively to test toxicity or disease pathophysiology in healthy individuals. Studies of all medical technologies measuring therapeutic outcomes as one of the objectives may be exempt from this criterion only if the disease or condition being studied is life-threatening and the patient has no other viable treatment options.
  3. The study is registered with the National Institutes of Health's National Library of Medicine's ClinicalTrials.gov.
  4. The study protocol describes the method and timing of release of results on all prespecified outcomes, including release of negative outcomes, and provides that release will be hastened if the study is terminated early.
  5. The study protocol describes how Medicare beneficiaries may be affected by the device under investigation and how the study results are or are not expected to be generalizable to the Medicare beneficiary population. Generalizability to populations eligible for Medicare due to age, disability, or other eligibility status must be explicitly described.
  6. The member, or the member's physician who is licensed, board certified, or board eligible and qualified to practice in the area appropriate to treat the member's condition, has requested a therapy that, based on two published studies from medical and scientific evidence, is likely to be more beneficial for the member than any available standard therapy.
  7. The physician's certification includes a statement of the medical and scientific evidence relied upon in certifying the recommendation.
  8. SFHP denied coverage of the recommended drug, device, procedure, or other therapy.
  9. The specific service recommended would be a covered service except for SFHP's determination that the therapy is experimental or investigational.
  10. Use the Standard Authorization Pathway

    When the request is determined not to be experimental or investigational, proceed with the regular review process under CO-22: Authorization Requests and Decision Timeframes and CO-66: Prior Authorization.

    • Do not apply the investigational-service pathway when the request is determined to be non-investigational.
    Documentation Required

    Required Clinical Documentation

    For a request determined to be experimental or investigational, obtain supporting documentation from the requesting physician before review.

    • Statement that standard services or procedures have been ineffective, medically inappropriate, or that no more beneficial covered standard service or procedure exists.
    • Explanation of why standard therapy would be ineffective, non-beneficial, or inappropriate, including risks and benefits, treatment goals, and patient-selection criteria.
    • Two published peer-reviewed medical or scientific studies, with the physician’s explanation of why they support greater benefit or a positive effect and why benefits outweigh harms.
    • Documentation that the attending physician is board certified or board eligible and qualified in the relevant area of practice.
    • Member’s informed-consent form when appropriate.
    • Relevant medical and treatment records, including test or study results and prior treatment.
    • Any other relevant data indicating the requested treatment’s effectiveness.
    Documentation Required

    External Review Certification

    For eligible members seeking external independent review, the physician must certify the qualifying condition, the lack of effective or medically appropriate standard therapy (or lack of a more beneficial covered standard therapy), and that the proposed therapy is likely to be more beneficial than available standard therapy.

    • The member must have a life-threatening or seriously debilitating condition.
    • The certification must identify the medical and scientific evidence relied upon.
    • The recommended service must otherwise be covered, except for SFHP’s experimental or investigational determination.
    • SFHP forwards eligible cases to MRIoA for external independent review.
    Documentation Required

    Document IDE Study Eligibility

    For Category A or Category B IDE studies, document that the study meets the applicable Medicare and regulatory requirements before requesting authorization.

    • Principal purpose is to test whether the device improves outcomes for appropriately selected patients.
    • Scientific and medical rationale is well supported or clarifies outcomes of an intervention already in common clinical use.
    • Results are not expected to unjustifiably duplicate existing knowledge.
    • Methodologically appropriate design and adequate enrollment to answer the research questions.
    • Sponsorship by an organization or individual capable of completing the study.
    • Compliance with 21 CFR Parts 50, 56, and 812, and 45 CFR Part 46.
    • Where applicable, the study is not exclusively testing toxicity or disease pathophysiology in healthy individuals, subject to the stated life-threatening-condition and no-viable-treatment exception.
    • Registration with ClinicalTrials.gov.
    • Protocol specifies the method and timing for releasing all prespecified outcomes, including negative outcomes and expedited release if terminated early.
    • Protocol explains effects on Medicare beneficiaries and explicitly addresses generalizability to beneficiaries eligible by age, disability, or other Medicare eligibility status.
    Denial Risk

    Conditions Supporting Experimental or Investigational Classification

    A service is experimental or investigational when any listed condition applies, including lack of unrestricted FDA or other governmental final market approval, inadequate evidence, inconclusive peer-reviewed evidence, or lack of benefit compared with established alternatives.

    • Approval granted only as an interim regulatory step does not substitute for final or unrestricted market approval.
    • SFHP defines adequate evidence as at least two medical and scientific documents indicating the proposed treatment is likely to benefit the member.
    • The service may be classified as investigational when evidence is insufficient or inconclusive regarding beneficial health outcomes or equivalence to established alternatives, including in a non-investigational setting.
    Denial Risk

    General Exclusion for Experimental Services

    SFHP generally denies experimental or investigational services because they do not meet the definition of medically necessary services and are not covered. The exclusion does not apply to qualifying clinical-trial services for prevention, detection, or treatment of cancer or other life-threatening conditions under CO-47.

    • SFHP may consider coverage under 22 CCR section 51303(h) only when all applicable exception criteria are documented.
    • The exception requires, among other conditions, failure or inadequacy of conventional therapy, qualified provider safety and success, lowest-cost medically appropriate service, no research-study protocol, and a reasonable expectation of significant life extension or preservation/restoration of daily function.
    Denial Risk

    IDE Study Denial Conditions

    Category A or Category B IDE study coverage may be denied when the study fails any applicable requirement for purpose, rationale, duplication, design, enrollment, sponsorship, human-subject protections, registration, outcome reporting, or Medicare-beneficiary relevance.

    • Prior authorization alone does not establish coverage; required study documentation and regulatory criteria must also be met.
    • Studies that do not satisfy the applicable Medicare IDE requirements are not eligible for coverage under this pathway.
    Denial Risk

    Incomplete Documentation May Result in Denial

    Missing or inadequate supporting documentation creates a denial risk. The record must explain why standard therapy is ineffective or inappropriate, address the proposed treatment’s risks and benefits and goals, and support the recommendation with required evidence and clinical records.

    • Incomplete clinical rationale, risk-benefit assessment, patient-selection criteria, or treatment goals may prevent authorization.
    • Failure to provide the required two published studies and explanation of their relevance may prevent authorization.
    • Missing provider qualifications, informed consent when appropriate, medical records, test results, or other effectiveness data may prevent authorization.
    The studies occur before testing in humans.
    Investigational Services
    Services includedDrugs, equipment, procedures, or services for which laboratory and animal studies are complete.
    Human studiesHuman studies are in progress, but testing is not complete.
    Evidence statusEfficacy and safety in human subjects are not yet established, and the service is not in wide usage.
    Qualifying Clinical Trial
    Trial scopeA clinical trial in any clinical phase.
    Conditions addressedRelated to the prevention, detection, or treatment of cancer or another life-threatening disease or condition.
    Qualifying pathwaysThe study must meet at least one specified criterion, such as qualifying approval or funding, an FDA-reviewed investigational new drug application, or an FDA-exempt drug trial.
    Independent Medical Review (IMR)
    Review typeExpert review of disputed health care services.
    ReviewerAn outside organization.
    Contracting authorityThe organization contracts with the Department of Managed Health Care (DMHC).
    Life-Threatening
    DefinitionA disease or condition in which the likelihood of death is high unless the course of the disease is interrupted.
    Alternative circumstanceA disease or condition with potentially fatal outcomes.
    Clinical endpointThe endpoint of clinical intervention is survival.
    Seriously Debilitating
    DefinitionDiseases or conditions that cause major irreversible morbidity.
    MorbidityThe resulting morbidity is major.
    ReversibilityThe morbidity is irreversible.
    Medical/Scientific Evidence
    Published evidencePeer-reviewed scientific studies published or accepted for publication by qualifying medical journals.
    Reference sourcesPeer-reviewed literature, biomedical compendia, other qualifying medical literature, and specified reference compendia.
    Government and meeting evidenceFindings, studies, or research from specified federal agencies and nationally recognized federal research institutes, plus peer-reviewed abstracts accepted for major medical association meetings.
    Life-Threatening
    High likelihood of deathDeath is likely unless the course of the disease is interrupted.
    Potentially fatal outcomeThe disease or condition may have a potentially fatal outcome.
    Intervention endpointThe endpoint of clinical intervention is survival.
    Medical/Scientific Evidence
    Medical journalsPeer-reviewed studies published or accepted for publication by journals meeting nationally recognized scientific-manuscript requirements and submitting most articles for outside expert review.
    Indexed literaturePeer-reviewed literature, biomedical compendia, and other medical literature meeting National Library of Medicine indexing criteria.
    Additional sourcesRecognized medical journals, specified reference compendia, qualifying federal research, and peer-reviewed abstracts accepted for major medical association meetings.
    Notice of Action (NOA)
    Document typeA formal letter to members.
    Possible actionThe letter informs members that a medical service has been denied, deferred, or modified.
    PurposeProvides formal notice of the decision affecting the medical service.
    Notice of Adverse Benefit Determination (NABD)
    DefinitionThe same type of formal notice as a Notice of Action.
    Notice contentIt concerns a medical service that has been denied, deferred, or modified.
    TerminologyDHCS retains the term Notice of Action for ease of understanding by members.
    Seriously Debilitating
    DefinitionDiseases or conditions that cause major irreversible morbidity.
    SeverityThe morbidity is major.
    DurationThe morbidity is irreversible.
    Terminal Illness
    ConditionAn incurable or irreversible condition.
    Probability of deathThe condition has a high probability of causing death.
    TimeframeDeath is expected within one year or less.